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Objectives: Methodological challenges in the evaluation of medical devices (MDs) may
be different for early and late technology adopter countries, as well as the potential
health technology assessment (HTA) solutions to tackle them. This study aims to provide
guidance to Central and Eastern European (CEE) countries on how to address key
challenges of HTA for MDs with special focus on the transferability of scientific evidence.
Methods: As part of the COMED Horizon 2020 project, a comprehensive list of issues
related toMDHTAwere identified based on a targeted literature review. Health technology
assessment issues which pose a greater challenge or require different solutions in late
technology adopter countries were selected. Draught recommendations to address
these issues were developed and discussed in a focus group. The recommendations
were then validated with a wider group of experts, including HTA and reimbursement
decision makers from CEE countries in May and June 2020.
Results: A consolidated list of 11 recommendations were developed in 3 major
areas: (1) clinical value assessment, focusing on the use of joint EU work, relying on
real-world evidence, use of coverage with evidence development schemes, transferring
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evidence from foreign countries and addressing the challenges of learning curve and
centre effect; (2) economic value assessment, covering cost calculation of complex
medical devices and transferability of economic evaluations of MDs; (3) HTA processes,
related to the frequent product modifications and various indications of MDs.
Conclusions: Central and Eastern European countries with limited resources for
conducting HTA, can benefit from HTA methods and evidence generated in early
technology adopter countries. Considering the appropriate reuse of international HTA
materials, late technology adopter countries can still implement HTA, even for MDs, which
have a more limited evidence base compared with pharmaceuticals.
Keywords: medical device (MD), health technology assessement (HTA), methodological challenge, transferability,
value assessment, Central-Eastern Europe (CEE), real world evidence (RWE)
INTRODUCTION
The use of HTA to improve the evidence base of health policy
decisions has been increasing across Europe. In almost all
countries where HTA has been introduced, it is mainly used to
support public coverage decisions of new pharmaceuticals, partly
because the availability of scientific evidence for medicines is
quite substantial compared with other technologies. However,
despite challenges (1), HTA has also been increasingly used to
support coverage decision of MDs, which necessitates specific
methodological guidelines for MDs (2).
Development and improvement of HTA methodologies is
on the top agenda of the European Union (EU). The EU
addressed the topic in several large scale projects financed
through 7th Framework and the Horizon 2020 Research
Programmes: the MedtechHTA project (3) was financed through
7th Framework Research Program, and the ongoing COMED
project is financed through the Horizon 2020 Program. The
COMED (Pushing the boundaries of Cost and Outcome analysis
of Medical Technologies) project has multiple objectives. First,
it aims to improve methods for economic evaluation for
medical devices by addressing most relevant challenges in
HTA of medical devices, second, to investigate health system
performance through analysis of variation in access to medical
technologies across different geographical areas; and finally, to
strengthen the use of economic evaluation of MDs in policy
making (4).
The COMED project put emphasis on extending the current
knowledge on the transferability of HTA methodologies and
reports for MDs especially across countries with different
economic status. This is highly needed, as HTA implementation
roadmaps of higher income Western European (WE) countries
may not be applicable in lower income European countries,
especially in Central and Eastern Europe for several reasons.
The health status of population in Central and Eastern
European (CEE) countries is significantly worse compared
with WE countries (5, 6), which indicates greater demand
for health technologies with substantial incremental health
gain. On the other hand, the availability of public health care
budgets to cover new technologies—including MDs—is more
limited in CEE countries. Therefore, these countries incur a
higher opportunity cost for inappropriate, not evidence-based
policy decisions.
Central and Eastern European countries have more
limited financial capacities for health technology assessment,
furthermore, there is lack of sufficient human resources
and expertise due to scarcity of post-graduate programs
(7). Due to the lower market potential related to budget
limitations, manufacturers tend to launch their new MDs later in
CEE than in WE countries, which creates an opportunity
for making use of accessible HTA reports prepared by
influential HTA institutes in early adopter countries of new
health technologies.
While the methodological challenges of WE and CEE
countries in the evaluation of MDs may be similar, potential
HTA solutions may be different due to the abovementioned
reasons. This document focuses on lower income and/or small-
size European countries which are late adopters of medical
devices due to their limited market potential (8), with special
focus on CEE EUmember states. Our objectives are (1) to explore
priority issues in conducting HTA for MDs, which are either
specific to CEE countries, or are present in all EU countries but
present greater challenges, or require different solutions in CEE
countries; and (2) to provide guidance to CEE countries on how
to address these challenges of MDs with special focus on the
transferability of scientific evidence.
Given these objectives, this document focuses on HTA
challenges that are more specific to medical devices as compared
with pharmaceuticals. Also, HTA challenges that are equally
relevant, and require similar solutions in early and later
technology adopter countries, are not in our scope. Finally, it is
not our intention to provide recommendations on how priority
setting should be implemented at the national level, including
whichMDs should be selected formandatoryHTA prior to policy
decisions and what should be the role of HTA in the pricing and
reimbursement of MDs.
On the other hand, MDs usually subjected to HTA
in the majority of countries are those which can deliver
incremental effectiveness or safety to patients. Therefore, our
recommendations may not be relevant to those decision support
MDs (e.g., shared decision-making tools, digital platforms),
which do not promise direct health gain.
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MATERIALS AND METHODS
A targeted literature review was conducted in Scopus to identify
a comprehensive list of issues of medical device HTA. A snowball
method was also used to identify further relevant studies among
the references of papers with full text review. The search strategy
used with the date of the search and number of hits are
summarised in Supplementary Material 1.
In a series of iterative brainstorming sessions, the results of
the literature review were discussed with senior experts with
experience in the HTA of MDs. Structured discussion was
conducted about all issues where the experts had to judge which
issues are relevant for European countries which are typically
late adopters of MDs. The relevant issues were selected by
considering certain requirements, such as non-redundancy, non-
overlap and preference independence. Issues that were equally
relevant to all European countries or do not require specific
recommendations in CEEwere excluded. The iterative discussion
was continued until all participants agreed with the inclusion of
the specific issue.
The iterative discussions were also used to propose draught
recommendations on how to manage the identified issues.
To provide sufficient details while preserving clarity, each
recommendation had a short form and a detailed description.
The original plan was to refine and validate the draught
list of recommendations in consecutive meetings with senior
international experts. However, in the COVID-19 outbreak
period we had to convert face-to-face meetings to virtual
platforms. Participants to these virtual meetings were identified
in an iterative process exploiting the professional networks of
COMED partners. The main selection criteria were familiarity
with the HTA ecosystem for MDs in late technology adopter
countries with efforts for maintaining balanced geographical
distribution of participants.
In April 2020 the list of issues and draught recommendations
were presented to a small group of HTA experts with
familiarity on national pricing and reimbursement processes
of MDs in CEE countries in a virtual focus group meeting.
After a thorough discussion, the descriptions of issues and
recommendations were improved based on the consensus
of participants.
The recommendations were validated with a wider group
of experts, including HTA and reimbursement decision
makers from CEE countries in May and June 2020. The
validation process started with a webinar to present the issues
and recommendations to a wider group of experts. Then,
participants of the focus group meeting and the webinar
in addition to COMED consortium members were asked
to provide written feedback on draught recommendations.
Finally, a virtual interactive meeting was organised to
discuss the written feedback and facilitate consensus
among participants.
Overall, 31 experts outside from the COMED consortium
representing 14 CEE countries (Bulgaria, Croatia, Czech
Republic, Greece, Hungary, Malta, Poland, Romania, Russia,




A total of 563 records were identified by the literature search.
After removal of duplicates and title-abstract screening, 20
articles were found to be eligible for this review. Integrating with
the 8 extra articles identified by the snowball method, in total, 28
articles qualified for a full-text review, and 19 were considered
eligible for the qualitative synthesis. The numbers of identified,
screened and excluded papers are shown in the flowchart in
Supplementary Material 2.
In the targeted literature review process, 33 issues were
identified with potential relevance for medical device HTA
in late adopter European countries. The 33 issues were
merged and reduced to 9 important issues with special
relevance to CEE countries after iterative brainstorming sessions
(Supplementary Material 3). The 9 issues were grouped to
clinical value assessment, economic value assessment and
HTA process.
Challenges and Recommendations for HTA
of MDs in Late Adopter Countries
Issue 1: Clinical Value Assessment
Challenge 1.1: Lower level of evidence for MDs
Evidence base is relatively limited for the majority of MDs
compared with pharmaceuticals due to several reasons.
Regulatory agencies do not mandate confirmatory efficacy and
safety data on MDs from randomised clinical trials (RCTs)
(1, 9–14). Hence, a substantial proportion of HTA reports
rely on surrogate outcomes in estimating the health gain,
often without proper validation (15). Although the recent EU
regulation (2017/745 of the European Parliament) (16) made
RCTs mandatory for Class IIb and III MDs, it is unforeseen
whether the evidence base of MDs can be increased to the
level of pharmaceutical, partly because blinding and proper
randomisation cannot be implemented for all MDs (2). In several
cases clinical trials for MDs are not adequately powered (i.e.,
sample size is too small) and/or the follow-up period is too
short for performing HTA analysis (15, 17–19). Finally, MDs
are often introduced into clinical practise quickly, especially in
high income countries with great market potential, often even
before the initiation of clinical trials (17). Then, when the MD is
introduced in late adopter CEE countries, it is no longer feasible,
or ethically justifiable to carry out RCTs (17).
Recommendation #1.1.a: Use relative effectiveness and safety
assessment from joint EU work or use rigorous relative
assessment from other jurisdictions. Relative effectiveness and
safety assessments (RESAs) from the joint work of EU member
states should be the starting point for CEE countries to judge
the clinical effectiveness and safety of a MD (20). If this is not
available, rigorous RESAs from other early adopter countries
may be transferred to CEE countries. When relying on results
from other countries, the absolute risk reduction should be
adjusted based on the local baseline risk and uncertainty of
the parameters should be explored with sensitivity analysis.
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Iterative reassessment should be considered when better evidence
becomes available.
Recommendation #1.1.b: Rely on real-world evidence, when
evidence from explanatory randomised clinical trials is limited.
If evidence from explanatory RCTs is limited, the best available
evidence should be synthetized with special attention to real-
world evidence (RWE) (21). Comparative observational studies,
patient registries or claims databases are examples of real-world
data (RWD) that can produce RWE on the effectiveness and
safety of MDs. However, appropriate methods of bias-adjustment
(e.g. counterfactual effect estimation) need to be applied (22).
RWE from early adopter countries may be transferred to
CEE countries.
Recommendation #1.1.c: Consider coverage with evidence
development, when the scientific evidence from randomised
clinical trials and real-world is premature. A possible solution for
the decision-makers to deal with uncertainty is to apply coverage
with evidence development (CED) schemes in a specified patient
population tracked over a defined period of time under explicit
requirement of further evidence generation, where the level
or continuation of reimbursement is based on the clinical and
economic outcomes achieved. Due to the administrative and
financial burden of implementing CED schemes in countries
with limited resources, they should be applied for MDs in areas
with high unmet medical need and public health priority. CED
schemes from early adopter countries may be transferred to
CEE countries.
Challenge 1.2: Limited transferability of real-world data and
real-world evidence from foreign countries
Even though RCTs may not reflect the effectiveness of MDs in
the real-world, they still represent the gold standard of evidence
generation for new technologies (23). However, more and more
stakeholders are exploring new areas of evidence generation
based on real-world data since rigour for its collection has
improved and standardisation has been initiated (24). While
RWD can increase the evidence base of health technologies,
RWD cannot completely replace RCTs. For quality assessment
purposes RWD and the derived RWE are virtually inseparable
(25–27). Due to limited availability of efficacy data from
explanatory RCTs and the methodological principles intrinsic
to RCTs (28, 29), the relative weight of RWD in the evidence
generation of MDs is greater compared with pharmaceuticals.
In CEE countries where MDs are introduced in later life
cycle stages, HTA of MDs could be accelerated through adapting
RWD to local jurisdictions. However, CEE countries have limited
power to access the original RWD from other countries (10, 30).
Therefore, transferability assessment cannot focus on RWD, but
on RWE.
It is highly important to note, that RWE is more subject
to local factors compared with protocol driven RCTs, partly
because the benefit of MDs is dependent on capacity constraints
for example in the follow-up care and heterogeneity of patient
pathways. Consequently, transferability of RWE is more limited
than transferability of evidence from RCTs.
Recommendation #1.2: Explore the feasibility of transferring RWE
to late technology adopter countries in a stepwise approach. In
order to overcome the uncertain quality and local relevance
of RWD, a stepwise approach is recommended to explore the
feasibility of transferring international RWE to CEE countries.
The first step should be the systematic search and collection
of potentially relevant RWEs, followed by an evaluation of the
equivalence of technologies presented in the study of origin
and local context. As a result, studies in which the technologies
have no major differences should be channelled into further
assessment. In the next step, the quality of evidence should be
evaluated by using quality assessment tools, such as GRADE
(31, 32), ROBINS-I (33) or the ISPOR initiative on RWE
transparency (34) and include only studies with appropriate
quality for quantitative synthesis (e.g., meta-analysis). As a last
step to guarantee applicability of evidence in local jurisdiction,
use of a transferability checklist [e.g., EUnetHTA Adaptation
Toolkit (35)] should be considered to evaluate the variation
in patient population, medical practise and health systems.
In CEE countries with capacity constraints in the follow-up
care and heterogeneous patient pathways, highly conservative
effectiveness estimates should be applied. On the other hand,
limited variability in the real-world outcomes across centres in
the country of origin indicates less dependence on local factors,
and consequently increased transferability of high-quality RWE
with appropriate comparator can be assumed to late technology
adopter countries.
Challenge 1.3: Limited transferability of surrogate endpoints
Surrogate endpoints (36) are intended to replace patient/clinical
relevant final endpoints, providing the possibility of using
indirect measurement in cases when direct measurement of
long-term clinical effects is not feasible. However, reliability of
surrogate outcomes in predicting effects on clinically meaningful
outcomes has to be validated, i.e., the treatment effect on a
surrogate endpoint needs to be predictive of the treatment
effect on the final clinical outcomes (15, 37). Due to differences
in populations and health care systems, surrogate outcome
predictions from other jurisdictions may not be directly
transferable to CEE countries without adjustment.
Recommendation #1.3: Reuse internationally validated
surrogate endpoints with extensive sensitivity analyses. Reuse
of internationally validated surrogate endpoints with extensive
sensitivity analyses is highly recommended in countries with
limited HTA resources. The use of surrogates should be limited
to HTAs using the same intervention, class of technology and
comparator as the validation. If modelled to determine cost-
effectiveness, the uncertainty of the extrapolation of surrogates
to final outcomes should be fully considered.
If the surrogate endpoint is endorsed by major regulatory
agencies (e.g., FDA) or HTA bodies (e.g., NICE, HAS, IQWIG,
CADTH) it should be accepted in the base case scenario.
International predictions for long-term outcomes should be
complemented with extensive sensitivity analysis by considering
a wide range of scenarios based on local factors.
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If major regulatory agencies or HTA bodies have not
endorsed the surrogate outcome, consider the best available
scientific evidence with special focus on surrogates validated by
international clinical societies for local assessment with more
conservative estimation of long-term benefits.
Challenge 1.4: Learning curve
The effectiveness of many MDs depends not only on the device
itself, but also on how it is used (17, 18, 38). A learning curve
is often associated with a MD, as user skills and training with
the new technology can have important implications on clinical
outcomes (1, 2, 13, 29, 39, 40). Central and Eastern European
countries are generally late adopters, so evidence on learning
curves frommore developed health systems may be available and
can be adapted for the assessment of a MD in a local context.
On the other hand, health care provision in CEE countries
is traditionally less standardised (i.e., protocol driven) and
due to resource constraints, “ad hoc” solutions are more
considered. During the launch period of new MDs, the support
of manufacturers in providing training or collecting outcomes
data in patient registries is often less intensive in countries with
limited market potential. These factors are expected to contribute
to longer learning curves, which can result in inferior outcome
initially due to incremental safety problems or treatment failures
in CEE compared with more advanced health care systems.
Recommendation #1.4: In the introductory period of MDs consider
inferior effectiveness and safety (1) based on learning curves from
other countries (2) and by using Bayesian approach. Learning
curve should be considered in the HTA of MDs. If local
evidence is not available, the transferability of learning curve
results from early adopter countries should be assessed. In
more resource constrained health systems in CEE countries,
differences in the length and shape of learning curves need to
be considered, and sensitivity analysis should be used to assess
different plausible scenarios. Another recommended method to
adjust the expected learning curves is the use of expert opinion
on the magnitude of inferior outcomes due to incremental safety
problems or complication rates in CEE countries, channelled
in the evaluation process using a Bayesian approach with
informative priors. The estimations can be updated once local
evidence is available. Shorter learning curves can be assumed,
if tailor-made manufacturer support is available for the medical
institution, for health care professionals, or for patients (e.g., in
case of self-administered MDs, such as wearables) during the
introductory period.
Challenge 1.5: Centre effect
Several external factors related to the ability of health care
professionals and institutes can influence the clinical effectiveness
of MDs. National health care systems are organised into different
centres, which obviously differ from each other. The centre
effect should be considered in a hierarchical order, as substantial
variation in provider skills may reside at the individual health
care professional, team or hospital level (13, 18, 41).
The institutional environment like the placement and size of
the centre, has dual impact on outcomes delivered by the medical
device. On one hand, the limited number of patients in smaller
centres can limit the ability of individuals to acquire appropriate
competencies, which extends the learning curve preventing
the maintenance of required skills to achieve maximum
performance. On the other hand, large volume and diversity of
services can influence the ability of institutes to exploit maximum
effectiveness of MDs. In this regard, economies of scale in
large specialised centres accelerates the adoption of MDs (42)
and allows institutes to employ more specialised operators and
ancillary staff, which ultimately improves outcomes and reduces
the average cost per case. In larger centres, economies of scope
with broader portfolio of services may improve health outcomes
in complicated cases (e.g., multimorbid patients) by ensuring
access to specialty services.
Recommendation #1.5: Consider the relative effectiveness and
safety of MDs in large volume centres with licenced health
care professionals. Since scale and scope of services matter,
primary judgement on the relative effectiveness and safety
of MDs should focus on large volume centres with licenced
health care professionals for a specific device. By introducing
a threshold on a minimum number of patients to be treated
at the institution and individual operator level, limiting the
number of centres and by defining quality standards, the
outcomes variation related to centre effect can be reduced. These
quality assurance tools may be transferred from early adopter
countries. Furthermore, by initiating a medical licencing system,
the maintenance of required expertise can be guaranteed. In
countries with decentralised health care system and small volume
centres, inferior effectiveness should be assumed, especially
where licenced health care professionals for the specific medical
device are not available. Additionally, an HTA model grounded
outcome-based risk sharing system can directly incentivize health
outcome improvement.
Issue 2: Economic Value Assessment
Challenge 2.1: Cost calculation of complex medical devices
for cost-effectiveness and budget impact analyses
The price transparency of complex MDs is limited due to
several factors. At first manufacturers of MDs can collect
income through different channels, and the prices for the
equipment, consumables and maintenance depend on strategic
considerations by manufacturers. At health care institutes the
equipment represents fixed costs and booked among capital
costs, while consumables and ad hoc maintenance expenses are
variable costs and booked among operating costs. As the average
cost is dependent on the economies of scale, it is not easy to
calculate the actual cost per intervention of complex MDs with
high upfront costs and unpredictable maintenance costs (43).
In addition, differences in local production functions among
hospitals further increases the variability of actual cost, especially
since resource utilisation within a hospital can also change over
time due to organisational changes and experience of health care
professionals. Finally, cost of necessary initial and continuous
training of health care professionals should also be taken into
account, when calculating the cost per case of complex MDs.
On the other hand, the availability of public health care budgets
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to cover new technologies—including MDs—is more limited in
CEE countries, and due to less advanced control mechanism,
prices of MDs in CEE countries may even be higher than in more
affluent WE countries.
Recommendation #2.1: HTA for MDs should be considered
primarily for national reimbursement decisions or centralised
procurement by taking into account average expected payments,
rather than actual costs. In countries with limitedHTA resources,
HTA for MDs should primarily focus on population level policies
such as national reimbursement or centralised procurement
decisions. To support the evidence base of national decisions,
cost calculations should not depend on non-transparent
price components, provider specific production functions and
economies of scale. Consequently, instead of actual costs, the
payment per case requested by health care providers or paid
by health care payers (e.g., fees or charges) should be used in
economic evaluations and budget impact analyses. If the focus
of the national HTA assessment is the procedure completed by
the MD rather than the MD itself, the payment for the procedure
should be used, which covers costs of the MD, institutional cost
and personnel cost as well.
Due to scarcity of HTA capacities at the local level, MD
procurement decisions by local institutionsmay not be supported
by full scope HTA reports. Still, decision-makers at local hospitals
should be able to judge whether the payment per case by
health care payers covers their expected local cost per case. This
necessitates return on investment and financial sustainability
calculation, which should be based on actual cost calculations by
taking into account local production functions and economies of
scale. On the other hand, if a CEE country still prefers hospital
based HTA in addition to national assessments, each hospital
should be able to calculate the actual cost of MDs per case
from their own perspective, which may not be transferable to
other hospitals.
Challenge 2.2: Limited transferability of economic evaluation
of MDs
Being late adopters of MDs, CEE countries can potentially rely
on HTA recommendations of early adopter countries. However,
even if a given technology considered cost-effective in a WE
country, it does not justify a positive recommendation in more
resource constrained CEE countries, partly due to differences
in the cost-effectiveness thresholds (44, 45). In addition, the
variability in the incremental cost-effectiveness ratio of health
technologies within different jurisdictions is documented in
several publications (46–48). Therefore, transferring results and
conclusions of an economic evaluation conducted in a higher
income country along with the differences in patient population,
comparator, patient pathways, outcomes, resource utilisation and
unit costs and potential differences in the device itself represents
several challenges (11, 49).
Recommendation #2.2: Adapt international economic models from
early technology adopter countries after transferability assessment.
In order to overcome the challenges of economic model
adaptation from early adopter to CEE countries, a stepwise
process is recommended. As a first step, a transferability of the
model should be evaluated in particular to local relevance of the
model concept and focusing on comparator, patient pathways
and long-term outcome estimation. After adjusting the model
to local circumstances, the use of country specific costs as a
mandatory step is recommended. This should incorporate local
patient pathways, average resource use in large centres and
local unit cost. During the estimation of health outcome, as
much local data as possible should be included to increase
the relevance of the prediction. Discount rate, time-horizon of
the assessment and other necessary input parameters should be
adjusted according to the local methodological guideline. As a
last step, a comprehensive sensitivity analysis is recommended to
explore the effect of parameter uncertainty.
Issue 3: HTA Process
Challenge 3.1: Frequent product modifications and
dynamic pricing
Unlike drugs, MDs often undergo several product modifications
over time, which may have an impact on health gain, costs
and patient experience (50). In late technology adopter CEE
countries, often modified versions of MDs are introduced and
have to be evaluated by HTA. In addition, prices of MDs more
often change over time due to the market entry of new products
(17, 39), iterative incremental developments over time (1, 2, 18,
39), and flexible procurement practises (17, 39). This raises the
question of whether and when these small improvements have to
be re-evaluated.
Recommendation #3.1: HTA should not be performed for a
particular version of a MD, but for the group of devices with the
same (or similar) characteristics. Full HTA is needed to support
the initial national reimbursement decision or centralised
procurement of a new MD. However, no HTA (or only fast track
HTA) is necessary if (1) a different manufacturer introduces a
similar MD with non-inferiority and no price increase; (2) the
price of a reimbursed MD is reduced; (3) an improved MD
emerges without price increase. A full HTA is still recommended,
if total cost of the procedures with a modified MD is increased
due to added value. A conservative approach should be followed
when assessing the added clinical value of modified MDs.
Challenge 3.2: Diverse and numerous clinical indications
of MDs
Several complex medical devices such as radiotherapy, robotic
surgery, imaging diagnostics, can be used for heterogeneous
patient populations in multiple indications. However, in
countries with limited HTA resources it is not possible to conduct
full scope HTA in all different indications.
Recommendation #3.2: Full scope HTA may not be necessary in
each potential indication, cost-effectiveness results in the most
prevalent indications can be generalised to indications with similar
expected health benefits. After exploring all potential indications,
the list should be narrowed to those indications which are
candidates for reimbursement by excluding indications with no
assumed incremental health gain or with low public priority.
Frontiers in Public Health | www.frontiersin.org 6 January 2021 | Volume 8 | Article 612410
Daubner-Bendes et al. Medical Device HTA in CEE
TABLE 1 | Consensus recommendations related to selected challenges of medical device HTA in late adopter countries.
Major issues Summary of challenges and recommendations
1. Clinical value assessment
(effectiveness and safety)
1.1 Lower level of evidence for MDs
- Use relative effectiveness and safety assessment from joint EU work or use rigorous relative assessment from other
jurisdictions
- Rely on real-world evidence, when evidence from explanatory randomised clinical trials is limited
- Consider coverage with evidence development, when the scientific evidence from randomised clinical trials and real-world
is premature
1.2 Limited transferability of real-world data and real-world evidence from foreign countries
- Explore the feasibility of transferring real-world evidence to late technology adopter countries in a stepwise approach
1.3 Limited transferability of surrogate endpoints
- Reuse internationally validated surrogate endpoints with extensive sensitivity analyses
1.4 Learning curve
- In the introductory period of medical devices consider inferior effectiveness and safety (1) based on learning curves from
other countries (2) and by using Bayesian approach
1.5 Centre effect
- Consider the relative effectiveness and safety of medical devices in large volume centres with licenced health
care professionals
2. Economic value assessment (cost
calculation, cost-effectiveness,
budget impact)
2.1 Cost calculation of complex medical devices for cost-effectiveness and budget impact analyses
- HTA for medical devices should be considered primarily for national reimbursement decisions or centralised procurement
by taking into account average expected payments (e.g., fee or charges) rather than actual costs
2.2 Limited transferability of economic evaluation of medical devices
- Adapt international economic models from early technology adopter countries after transferability assessment
3. HTA process 3.1 Frequent product modifications and dynamic pricing
- HTA should not be performed for a particular version of a medical device, but for the group of devices with the same (or
similar) characteristics
3.2 Diverse and numerous clinical indications of medical devices
- Full scope HTA may not be necessary in each potential indication, cost-effectiveness results in the most prevalent
indications can be generalised to indications with similar expected health benefits
MDs, medical devices; HTA, health technology assessment.
Full scope HTA with detailed cost-effectiveness analysis has to
be conducted in the most prevalent indications. If the MD is
cost-effective in the most prevalent indications, in case of limited
HTA capacities, it is an acceptable compromise to generalise cost-
effectiveness evidence in the most prevalent indications to other
indications with similar estimated health gain. However, budget
impact analysis is needed for the entire target patient population
eligible for public coverage.
The recommendations described above are summarised in
Table 1.
DISCUSSION
Those European countries which are late adopters of new
technologies usually have more limited resources not only
for covering high-cost innovative technologies from public
resources, but also for conducting HTA to substantiate their
health policy decisions with appropriate evidence base. However,
delays in the uptake of new technologies create an opportunity
to benefit from HTA methods and reports generated in
early technology adopter countries. Therefore, considering the
appropriate reuse of international HTAmaterials, late technology
adopter countries can still implement HTA, even for MDs, which
havemore limited evidence base comparedwith pharmaceuticals.
As a general recommendation, CEE countries should be
encouraged to contribute to joint work to extend the evidence
base of MDs, including generation of RWE, validation of
surrogate endpoints and exploratory research on learning curves.
The increased participation of CEE centres in international
collaborative research projects can improve the knowledge on
the transferability of scientific evidence related to MDs. CED
schemes should also be considered in CEE, however, further
research is needed on which elements of CED schemes from early
adopter countries are transferable to late adopter countries.
Recommendations given in this report may provide guidance
for policy-makers on how standards for HTA of MDs
should be improved in lower income countries. Although
adaptation of these recommendations should remain in national
competencies, if these proposals are translated into routine
practise, manufacturers will have more clarity on what they need
to deliver to facilitate the market access of their new MDs in
countries with less market potential. Recommendations are not
equally relevant for all different types of MDs.
Ultimately, we hope that applying these recommendations
can lead to better care for patients with greater need for health
improvement in more deprived European countries by reducing
the opportunity cost of inappropriate coverage decisions.
Although in our guidance we focused mainly on lower income
European countries especially in CEE, these recommendations
can be valid to any lower income country outside Europe,
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which are also late adopters of MDs due to their limited market
potential, and also to any small country, which have limited
human and financial resources to support coverage decisions
with HTA evidence.
It should be noted that our recommendations are based
primarily on the opinion of relatively small-sized expert group,
which is the most important limitation of our study. However,
focusing on commonalities and not differences across countries
with highly experienced HTA professionals in the deliberative
process facilitated the replicability of our conclusions. Still, our
recommendations cannot be equally generalizable to all different
categories of MDs. Hence future research, especially at the
national level targeting different types of MDs, should test the
appropriateness of our recommendations, which may necessitate
additional recommendations for specific groups of MDs.
Overall, our guidance should be viewed only as a first step
in a multi-stakeholder dialogue about HTA practises of MDs in
lower income European countries, which can be strengthened by
voluntary regional collaboration in HTA.
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